Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.64 |
| ▸ | ITGAV | P06756 | 4/20 | 0.64 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.64 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.55 |
| ▸ | MC4R | P32245 | 10/20 | 0.50 |
| ▸ | MC5R | P33032 | 10/20 | 0.50 |
| ▸ | MC3R | P41968 | 10/20 | 0.50 |
| ▸ | MC1R | Q01726 | 10/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744481 | 1.00 | ITGB3 (0.64) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL16177741 | 0.93 | ITGB3 (0.61) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14885782 | 0.93 | ITGB3 (0.61) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14075719 | 0.90 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL16995729 | 0.88 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14585830 | 0.88 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL24285406 | 0.88 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL10138534 | 0.88 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL15397366 | 0.88 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL18968795 | 0.88 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486372-B2 | Cyclic azapeptides as integrin markers and methods of using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486372-B2 | Cyclic azapeptides as integrin markers and methods of using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8133472-B2 | Cyclopeptides containing RGD mimetics as imaging markers for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8043601-B2 | Cyclic azapeptides as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGB1 3/4885 |
| US-20110256057-A1 | Cyclic Azapeptides as Integrin Markers and Methods of Using | ITGAV, ITGB3, ITGA2B | ITGB3 2/4885ITGAV 1/4885ITGB1 4/4885 |
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | ITGB1, ITGAM, ITGB3 | ITGB3 3/4885ITGAV 8/4885ITGB1 1/4885 |
| US-20090074664-A1 | CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS | ITGAV, ITGB3, ITGA2B | ITGB3 2/4885ITGAV 1/4885ITGB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.